Nuplazid
Drug timelines are a Plus or Pro feature.
24 regulatory and trial events tracked for Nuplazid, covering 2016-04-29 to 2026-03-16. Get the full timeline:
Most recent: Clinical Trial Update: Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. [Phase 2]